Aileron Therapeutics Inc (NASDAQ:ALRN)

3.17
Delayed Data
As of Jan 23
 0.00 / 0.00%
Today’s Change
1.79
Today|||52-Week Range
15.00
+33.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$15.4M

Company Description

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company engaged in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Watertown, MA.

Contact Information

Aileron Therapeutics, Inc.
285 Summer Street
Boston Massachusetts 02210
P:(617) 995-0900
Investor Relations:

Employees

Shareholders

Other institutional8.06%
Mutual fund holders4.35%
Individual stakeholders--

Top Executives

Manuel C. Alves AivadoPresident, Chief Executive Officer & Director
Susan L. DrexlerChief Financial Officer
Andres BrainskyVice President-Clinical Development
David Allen AnnisSenior Vice President-Research